Ocular Therapeutix, Inc. (OCUL) P/S ratio

P/S ratio today
21.7×

Ocular Therapeutix, Inc. (OCUL) trades at 21.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 43.8×. That is 106.3% higher than the 21.2× of fiscal 2024. Figures as of 18 Nov 2026, 10:46 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
21.7×
P/S ratio, fiscal 2025
43.8×
Change on fiscal 2024
+106.3%
Highest on record
43.8×fiscal 2025
Lowest on record
4.5×fiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Ocular Therapeutix, Inc. P/S ratio, in more detail

Today's figure is 50.4% below the fiscal 2025 year-end.

Across the 4 fiscal year-ends on record (2022–2025), the highest was 43.8× in fiscal 2025 and the lowest 4.5× in fiscal 2022. Today's P/S ratio is higher than at 75% of the 4 fiscal year-ends on record; their median is 13.9×.

History · 4 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Ocular Therapeutix, Inc. P/S ratio, year by year

Ocular Therapeutix, Inc. (OCUL) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today21.7×—$6.02—
202543.8× 106.3% up$12.14$0.28
202421.2× 224.7% up$8.54$0.40
20236.5× 44.8% up$4.46$0.68
20224.5×—$2.81$0.62
2021——$6.97—
2020——$20.70—
2019——$3.95—
2018——$3.98—
2017——$4.45—
2016——$8.37—
2015——$9.37—
2014——$23.52—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on OCUL

Ocular Therapeutix, Inc., figure by figure

Ocular Therapeutix, Inc. (OCUL) overview: price, valuation and scorecard

Ocular Therapeutix, Inc. P/S ratio: questions and answers

What is Ocular Therapeutix, Inc.'s P/S ratio?

Ocular Therapeutix, Inc. (OCUL) trades at 21.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 43.8×. That is 106.3% higher than the 21.2× of fiscal 2024.

Is Ocular Therapeutix, Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 75% of the 4 fiscal year-ends on record; their median is 13.9×.

What are the highest and lowest P/S ratio figures on record for Ocular Therapeutix, Inc.?

Across the 4 fiscal year-ends on record (2022–2025), the highest was 43.8× in fiscal 2025 and the lowest 4.5× in fiscal 2022.

How is Ocular Therapeutix, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Ocular Therapeutix, Inc. it is on record here for 4 fiscal years, 2022 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ocular Therapeutix, Inc. (OCUL) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/OCUL/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.